Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses.

ABSTRACT:

Background

Ixabepilone may retain activity in paclitaxel-resistant disease. We previously reported improved response rates (ORR), progression-free (PFS), and overall survival (OS) conferred by ixabepilone+bevacizumab (IXA + BEV) compared to monotherapy (IXA) in heavily pre-treated ovarian cancers. We now describe a mature data set. Subset analyses were performed in patients with different taxane sensitivities and dose modifications.

Methods

Patients previously treated with paclitaxel were stratified by prior BEV and randomized to receive IXA 20 mg/m² days 1,8,15 ± BEV 10 mg/kg days 1,15 of a 28-day cycle in a multi-site prospective randomized phase 2 trial.

Results

Thirty-seven patients were randomized to IXA and 39 patients to IXA + BEV. At the final data

SUBMITTER: Roque DM 

PROVIDER: S-EPMC11523995 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature